A new pill, HMTM, may be approved by the NHS to slow Alzheimer's, after showing promise in preventing tau protein clumps.

A new daily pill called Hydromethylthionine mesylate (HMTM), developed by British firm TauRX, may be approved for use by the NHS to slow Alzheimer's progression. Preclinical studies show it prevents tau protein clumps linked to cognitive decline. Regulators will decide in April if the pill, which could offer a major advancement in dementia treatment, should be made available on the NHS.

3 months ago
6 Articles